Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models

Highlights • Metronomic ZOL on tumor growth and osteolysis in breast cancer mice were studied. • Metronomic ZOL (zoledronic acid) resulted in a significant reduction of tumor burden. • Metronomic ZOL did not promote lung or liver metastasis. • Metronomic ZOL protected the bone from breast cancer-ind...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2013-10, Vol.339 (1), p.42-48
Main Authors: Luo, Ke-Wang, Ko, Chun-Hay, Yue, Grace G.L, Lee, Michelle Y.Y, Siu, Wing-Sum, Lee, Julia K.M, Shum, Wai-Ting, Fung, Kwok-Pui, Leung, Ping-Chung, Li, Gang, Evdokiou, Andreas, Lau, Clara B.S
Format: Article
Language:English
Subjects:
Acids
Administration, Metronomic
animal models
Animals
Anti-osteolysis
Antineoplastic Agents - administration & dosage
Bioluminescence
Bone and Bones - diagnostic imaging
Bone and Bones - pathology
Bone cancer
Bone Density Conservation Agents - administration & dosage
Breast cancer
breast neoplasms
Cell adhesion & migration
Conventional
Diphosphonates - administration & dosage
Drug dosages
Female
Fractures
Hematology, Oncology and Palliative Medicine
Humans
Imidazoles - administration & dosage
Laboratory animals
Liver
Mammary Neoplasms, Experimental - diagnostic imaging
Mammary Neoplasms, Experimental - drug therapy
Mammary Neoplasms, Experimental - pathology
Medical imaging
Metastasis
Metronomic
Mice
Mortality
Neoplasm Metastasis
Osteolysis - diagnostic imaging
Osteolysis - drug therapy
Osteolysis - etiology
Osteolysis - pathology
Radiography
Rodents
Spinal cord
Tomography
Tumor Burden - drug effects
Zoledronic acid
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Metronomic ZOL on tumor growth and osteolysis in breast cancer mice were studied. • Metronomic ZOL (zoledronic acid) resulted in a significant reduction of tumor burden. • Metronomic ZOL did not promote lung or liver metastasis. • Metronomic ZOL protected the bone from breast cancer-induced osteolysis. • This dosing schedule of ZOL showed great potential against metastatic breast cancer.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2013.07.024